Generic Name and Formulations:
Sulfur hexafluoride lipid-type A microspheres (25mg of lipid-type A lyophilized pwd with 60.7mg of sulfur hexafluoride gas); per vial; for IV or intravesical inj after reconstitution.
Indications for LUMASON:
For use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. For use in ultrasonography of the liver to characterize focal liver lesions in adult and pediatric patients. For use in ultrasonography of the urinary tract for evaluation of suspected or known vesicoureteral reflux in pediatric patients.
See full labeling. Echocardiography: 2mL via IV bolus inj. Ultrasonography of the liver: 2.4mL via IV inj. Both: may repeat dose once if needed. Follow each inj with 5mL normal saline flush.
See full labeling. Ultrasonography of the liver: 0.03mL/kg via IV inj; max 2.4mL per inj. May repeat dose once if needed. Follow each inj with 5mL normal saline flush. Ultrasonography of the urinary tract: 1mL via intravesical bolus inj through the urinary catheter. The bladder may be refilled with normal saline for second cycle of voiding and imaging, without the need of a second Lumason inj.
Serious cardiopulmonary reactions.
Do not administer by intra-arterial inj. Risk of cardiopulmonary reactions (may be fatal); increased risk in those with unstable conditions (eg, acute MI, coronary artery syndromes, CHF, ventricular arrhythmias). Have resuscitation equipment and trained personnel readily available. Assess patients with cardiac shunts for embolic phenomena post inj. Monitor for hypersensitivity reactions. Not recommended for use at mechanical indices >0.8; high index values may lead to ventricular arrhythmias. Pregnancy, nursing mothers: no data.
Headache, nausea, dysgeusia, inj site pain, feeling hot; cardiopulmonary reactions, hypersensitivity reactions.
Kit—1 (one vial + diluent + mini-spike)
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Bleeding Disorder Treatments: Hemophilia A
- Guideline Recommendations Offer No OS Benefit for Younger Patients With Rectal Cancer
- Bleeding Disorder Treatments: von Willebrand Disease
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|